Mentice

14.00 SEK

+1.08 %

Less than 1K followers

MNTC

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+1.08 %

+4.09 %

+4.87 %

+3.70 %

+12.00 %

-34.38 %

-71.65 %

-84.84 %

-79.03 %

Mentice operates in the medical technology sector. The company develops medical instruments for endovascular simulation and for training sessions in surgery. The programs are developed for use in educational purposes among hospitals and institutes. The largest operations are found in North America and Europe. In addition to the main business, opportunities for leasing, support, and technical service are offered. The headquarters are located in Gothenburg.

Market cap

393.76M SEK

Turnover

63K SEK

Revenue

279.09M

EBIT %

-9.88 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

7.5

2026

Interim report Q1'26

26.5

2026

General meeting '26

23.7

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Press release2/27/2026, 7:19 AM

DNB Carnegie Access: Mentice: Ending 2025 on a high note – Q4 review

Regulatory press release2/26/2026, 8:00 PM

Communique from extraordinary shareholders’ meeting in Mentice AB

Press release2/26/2026, 7:17 AM

DNB Carnegie Access: Mentice: Firing on all cylinders – Q4 initial take

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/26/2026, 6:00 AM

Mentice publishes the company’s year-end report for the period January–December 2025

Press release2/12/2026, 2:00 PM

Mentice to Present the Company's Year-End Q4 Report 2025 via Webcast

Regulatory press release2/3/2026, 2:52 PM

Notice to attend the extraordinary shareholders’ meeting in Mentice AB

Press release1/8/2026, 7:42 AM

DNB Carnegie Access: Mentice: Look beyond FX headwinds – Q4 preview

Press release11/7/2025, 6:32 AM

DNB Carnegie Access: Mentice: Starting to show strong operating leverage – Q3 review

Press release11/6/2025, 7:45 AM

DNB Carnegie Access: Mentice: Shows strong operational leverage – Q3 initial take

Regulatory press release11/6/2025, 6:00 AM

Mentice publishes the company’s interim report for the period July – September 2025

Regulatory press release10/23/2025, 1:30 PM

Nomination Committee has been appointed for Mentice AB (publ) Annual General Meeting 2026

Press release10/23/2025, 7:00 AM

Mentice to Present Q3 2025 Interim Report via Webcast

Press release10/3/2025, 6:53 AM

DNB Carnegie Access: Mentice: Cost-control focus – Q3 preview

Press release8/21/2025, 6:15 AM

Mentice receives approximately SEK 31.95 million through oversubscribed rights issue

Press release8/4/2025, 1:00 PM

Mentice publishes information document regarding rights issue

Press release8/1/2025, 11:00 AM

Mentice receives an additional Subscription Commitment of 3.4 MSEK in the upcoming Rights Issue

Press release7/25/2025, 7:53 AM

DNB Carnegie Access: Mentice: Shows resilience in adj. EBITDA – Q2 review

Press release7/24/2025, 11:05 AM

DNB Carnegie Access: Mentice: Recording from earnings call Q2 (25)

Press release7/24/2025, 7:07 AM

DNB Carnegie Access: Mentice: FX and comparables tougher than feared – Q2 initial take

Regulatory press release7/24/2025, 6:00 AM

Mentice resolves on a rights issue of approximately SEK 31.95 million

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.